|
CoronaVac
|
Sinovac
|
Inactivated
|
Copies of killed COVID-19 viruses are administered. The individual’s
immune system recognizes these inactivated viral particles as foreign
antigens and initiates an immune response against it.
|
51% efficacy against symptomatic SARS-CoV-2 infection, 100% efficacy
against severe COVID-19, and 100% efficacy against hospitalization
starting 14 days after receiving the second dose
|
|
|
Covilo
|
Sinopharm (Beijing)
|
|
|
Efficacy of 79% against symptomatic SARS-CoV-2 infection 14 days after
the second dose
|
|
|
Covaxin or BBV152
|
Bharat Biotech
|
|
|
Efficacy of 78% 14 days post dose 2; 93% efficacy against severe
disease
|
|
|
Covishield
|
Serum Institute of India
|
Non replicating viral vector
|
The SARS-CoV-2 genetic material is packaged inside another harmless
virus that cannot copy itself, and this preparation is administered as
the vaccine
|
76% post 15 days after 2nd dose
|
|
|
Vaxzevria
|
Oxford/AstraZeneca
|
|
|
91.4% efficacy against hospitalization, 91.1% efficiency against ICU
admissions, and 92.3% against the death
|
|
|
Ad26.COV2.S
|
Janssen (Johnson & Johnson)
|
|
|
efficacy of 85.4% against critical illness and 93.1 % against
hospitalization after 28 days post-inoculation
|
|
|
Comirnaty or Tozinameran or BNT162b2
|
Pfizer/BioNTech
|
RNA vaccine
|
The SARS-CoV-2 genetic material (RNA encoding viral spike protein in
this case) is administered as the vaccine, which is utilized by the
cells to synthesize viral proteins. Antibodies are then generated
against these viral proteins.
|
95% efficacy after 2 doses of administration
|
|
|
Spikevax or mRNA-1273
|
Moderna
|
|
|
Shows 94.1% efficacy
|
|
|
COVOVAX
|
Serum Institute of India
|
Protein subunit
|
Isolated and purified viral proteins alone are administered as the
vaccine and antibodies are produced against these viral proteins.
|
More than 90% efficacy
|
|
|
Nuvaxovid or NVX-CoV2373
|
Novavax
|
|
|
90% efficacy against mild, moderate and severe disease.
|
|